Alzheimer's Disease & Dementia
An Introduction to Alzheimer's Disease & Dementia
Major advances in the understanding of the pathogenesis of Alzheimer’s disease (AD), the most common form of dementia, have occurred over recent years, but the need for truly disease-modifying therapies remains. Novel pharmacotherapy strategies under investigation include the repurposing of medications used to treat non-AD illnesses and multi-target-directed ligands, offering promise in this challenging treatment landscape.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Alzheimer's Disease & Dementia Content
Jeffrey Cummings, AAIC 2020 – Microbiome in Alzheimer’s Disease
Valued editorial board member Jeffrey Cummings (University of Nevada, Las Vegas [UNLV], and Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) shares exciting insights from the session he co-chaired at AAIC20 entitled ‘Microbiome in Alzheimer’s Disease: Pathogenesis and Treatment Implications’. Questions 1. Could you give us a brief overview of the role of […]
Foreword – US Neurology, Spring 2020
US Neurology. 2020:16(1):9
Welcome to the spring edition of US Neurology. During the COVID-19 pandemic, which has had a substantial impact on patients with neurological disease, as well as providing significant challenges to healthcare providers, we hope our journal provides reason for optimism by highlighting recent conceptual and practical clinical advances. We begin with an expert interview, in which […]
Bengt Winblad, EAN 2020 – Emerging therapeutic targets for Alzheimer’s disease
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including emerging therapeutic targets for Alzheimer’s disease (AD) and the role of the FKBP51-Hsp90 complex in underlying pathophysiological processes. Questions 1. What are the most promising emerging therapeutic targets […]
Bengt Winblad, EAN 2020 – Targeting Beta-amyloid for the Treatment of Early Alzheimer’s
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the recent resurrection of an investigational human monoclonal antibody targeting beta-amyloid for the treatment of early Alzheimer’s disease (AD). Question What is your opinion of the resurrection of […]
Bengt Winblad, EAN 2020 – Overview of the MOPEAD Project
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the MOPEAD initiative. MOPEAD (Models of Patient Engagement for Alzheimer’s disease), aims to deliver a step-change in AD patient engagement strategies and a paradigm shift from late-stage diagnosis […]
Molecular Pathogenesis of Alzheimer’s Disease
US Neurology. 2019;15(1):14–6.
Alzheimer’s disease was first described in 1906, and yet we have still not fully elucidated the pathogenesis of the condition. It is known that the disease is characterized by the polymerization of amyloid β-peptide (Aβ), leading to the formation of plaques.1,2 The cascade of events initiated by Aβ polymerization eventually leads to progressive neurodegeneration and […]
Latest Developments in Preclinical Alzheimer’s Disease
US Neurology. 2019;15(1):12–3
In the last decade, our understanding of Alzheimer’s disease has advanced considerably. Thanks to evolving biomarker research, it is now recognized that a preclinical stage occurs before the occurrence of symptoms.1 This preclinical phase has become the focus of considerable research efforts as early intervention is likely to offer the best chances of a cure. […]
ADI – Dementia Care and COVID-19
Videos produced by and shared with kind authorisation of Alzheimer’s Disease International (ADI). Professor Huali Wang, Executive Vice President of ADI’s member association in China, Alzheimer’s Disease Chinese (ADC), explains how China has addressed the specific challenges of people living with dementia during the COVID-19 outbreak, and how this advice can be used in other […]
Cerebrovascular Lesions in Alzheimer-associated Diseases – A Neuropathological Study with 7.0-tesla Magnetic Resonance Imaging
European Neurological Review. 2018;13:(2):100–2 DOI: https://doi.org/10.17925/ENR.2018.13.2.100
The occurrence of mixed dementias is significantly related to the aging process.1 Their brain pathology accounts for most cases in community-dwelling older persons.2 Mixed dementias are clinically under-recognised and need neuropathological confirmation.3 The most frequent types are those composed of Alzheimer’s dementia (AD) associated with cerebral amyloid angiopathy (CAA), cerebral arteriosclerotic micro-angiopathy (CAMA), and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!